These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
170 related articles for article (PubMed ID: 38273969)
1. Avapritinib treatment of aggressive systemic mastocytosis with a novel KIT exon 17 mutation. Sandow L; Town A; Heinrich MC Leuk Res Rep; 2024; 21():100409. PubMed ID: 38273969 [TBL] [Abstract][Full Text] [Related]
8. Antineoplastic efficacy profiles of avapritinib and nintedanib in Degenfeld-Schonburg L; Gamperl S; Stefanzl G; Schruef AK; Sadovnik I; Bauer K; Smiljkovic D; Eisenwort G; Peter B; Greiner G; Hadzijusufovic E; Schwaab J; Sperr WR; Hoermann G; Kopanja S; Szépfalusi Z; Hoetzenecker K; Jaksch P; Reiter A; Arock M; Valent P Am J Cancer Res; 2023; 13(2):355-378. PubMed ID: 36895976 [TBL] [Abstract][Full Text] [Related]
9. Response Criteria in Advanced Systemic Mastocytosis: Evolution in the Era of KIT Inhibitors. Shomali W; Gotlib J Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33804174 [TBL] [Abstract][Full Text] [Related]
10. Proposed European Competence Network on Mastocytosis-American Initiative in Mast Cell Diseases (ECNM-AIM) Response Criteria in Advanced Systemic Mastocytosis. Gotlib J; Schwaab J; Shomali W; George TI; Radia DH; Castells M; Carter MC; Hartmann K; Álvarez-Twose I; Brockow K; Bonadonna P; Hermine O; Niedoszytko M; Hoermann G; Sperr WR; Elberink HO; Siebenhaar F; Butterfield JH; Ustun C; Zanotti R; Triggiani M; Schwartz LB; Lyons JJ; Orfao A; Sotlar K; Horny HP; Arock M; Metcalfe DD; Akin C; Lübke J; Valent P; Reiter A J Allergy Clin Immunol Pract; 2022 Aug; 10(8):2025-2038.e1. PubMed ID: 35724948 [TBL] [Abstract][Full Text] [Related]
11. Avapritinib for the treatment of KIT mutation-negative systemic mastocytosis. Azad F; Zhang J; Wang E Proc (Bayl Univ Med Cent); 2023; 36(1):81-82. PubMed ID: 36578586 [TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of avapritinib in previously treated patients with advanced systemic mastocytosis. Reiter A; Schwaab J; DeAngelo DJ; Gotlib J; Deininger MW; Pettit KM; Alvarez-Twose I; Vannucchi AM; Panse J; Platzbecker U; Hermine O; Dybedal I; Lin HM; Rylova SN; Ehlert K; Dimitrijević S; Radia DH Blood Adv; 2022 Nov; 6(21):5750-5762. PubMed ID: 35640224 [TBL] [Abstract][Full Text] [Related]
13. Inhibitory effects of midostaurin and avapritinib on myeloid progenitors derived from patients with KIT D816V positive advanced systemic mastocytosis. Lübke J; Naumann N; Kluger S; Schwaab J; Metzgeroth G; Evans E; Gardino AK; Lengauer C; Hofmann WK; Fabarius A; Cross NCP; Reiter A; Jawhar M Leukemia; 2019 May; 33(5):1195-1205. PubMed ID: 30911112 [TBL] [Abstract][Full Text] [Related]
14. Systemic Mastocytosis: Following the Tyrosine Kinase Inhibition Roadmap. Piris-Villaespesa M; Alvarez-Twose I Front Pharmacol; 2020; 11():443. PubMed ID: 32346366 [TBL] [Abstract][Full Text] [Related]
15. A new humanized in vivo model of KIT D816V+ advanced systemic mastocytosis monitored using a secreted luciferase. Bibi S; Zhang Y; Hugonin C; Mangean MD; He L; Wedeh G; Launay JM; Van Rijn S; Würdinger T; Louache F; Arock M Oncotarget; 2016 Dec; 7(50):82985-83000. PubMed ID: 27783996 [TBL] [Abstract][Full Text] [Related]